Look back at news to Sept 16

By Barbara Obstoj-Cardwell. Editor

Horizon Pharma is a very active biopharmaceutical business as it is very acquisitive, wrote ‘Value Investor’ on the Seeking Alpha blog. The company just announced  another major purchase, Raptor Pharmaceuticals, after it has made numerous acquisitions in previous years. These kind of deals have resulted in spectacular sales growth, as severe dilution has significantly reduced the benefits of this strategy on a per share basis.

This $9 per share, or $800 million, deal gives the company access to rare disease treatments. Raptor's Procysbi and Quinsair capsules and rights will add an anticipated $125 to $135 million in sales for 2016. While these sales are showing decent growth, note that Raptor actually posted operating losses of around $50 million in 2015.